A Pharmacoeconomic Analysis to Determine the Relative Cost-effectiveness of Timolol 0.5%, Brinzolamide 1% and Brimonidine 0.2% Eye Drops in Treatment of Primary Open Angle Glaucoma/Ocular Hypertension

Simple item page
dc.contributor.authorSehgal, VKen_US
dc.contributor.authorVashisht, Ten_US
dc.contributor.authorSingh, Gen_US
dc.contributor.authorSharma, Nen_US
dc.date.accessioned2019-11-04T04:58:23Z
dc.date.available2019-11-04T04:58:23Z
dc.date.issued2019-07
dc.description.abstractAim: A pharmacoeconomic analysis to determine the relative cost-effectiveness of timolol 0.5%, brinzolamide 1% and brimonidine 0.2% eye drops in treatment of Primary Open Angle Glaucoma (POAG)/ocular hypertension (OHT). Settings and Design: Comparative, open, randomized, parallel group prospective study. Materials and Methods: 60 patients of POAG or ocular hypertension were included in this study. Time period of study was 6 weeks. 60 eyes of 60 patients were included in the study. Patients were divided randomly into 3 groups of 20 each. Patients in group A, B and C received timolol, brinzolamide and brimonidine respectively. One drop of each medication was instilled twice a day at 9 am and 9 pm daily for 6 weeks. IOP was measured on day 0 at 9 am (before administration of drugs) and then at 11 am, to get baseline IOP. IOP was again measured on subsequent visits at 9 am and 11 am. Treatment outcome was number of mm Hg fall in IOP induced by the study drug. The daily cost of each drug was calculated by maximum retail price and the average number of drops per bottle. The cost‑effectiveness was then calculated as the cost of drug/mm Hg fall in IOP. Statistics: Paired ‘t’ test was used to analyze the parameters within the group. Independent samples t‑test was used to compare the efficacy of drugs with each other. Results: The % reduction of brimonidine, timolol and brinzolamide at end of 6 weeks was 21.43 ± 3.06%, 24.87 ± 2.46% and 18.78 ± 1.73% respectively. Timolol was superior in efficacy to other two drugs. The difference was statistically significant between the efficacy of timolol and brinzolamide (p < 0.001) as well as timolol and brimonidine (p = 0.003). There was no statistical significant difference in the efficacy of brimonidine when compared to brinzolamide (p=0.26). Timolol (5.87 ± 0.83 Rs/mm lowering after 6 weeks) was found to be most cost-effective followed by brimonidine (46.83 ± 7.37) and then brinzolamide (60.49 ± 6.77) in lowering IOP. Conclusion: All three drugs under the present study are useful in the treatment of POAG/OHT, but timolol is a better choice than other two drugs because of greater reduction in IOP and greater cost-effectiveness.en_US
dc.identifier.affiliationsDepartment of Pharmacology, BFUHS, GMC Patiala – 147001, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, BFUHS, GMC Patiala – 147001, Punjab, India; vashisht.tushar@gmail.comen_US
dc.identifier.affiliationsDepartment of Ophthalmology, BFUHS, GMC Patiala – 147001, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacology, BFUHS, GMC Patiala – 147001, Punjab, Indiaen_US
dc.identifier.citationSehgal VK, Vashisht T, Singh G, Sharma N. A Pharmacoeconomic Analysis to Determine the Relative Cost-effectiveness of Timolol 0.5%, Brinzolamide 1% and Brimonidine 0.2% Eye Drops in Treatment of Primary Open Angle Glaucoma/Ocular Hypertension. International Journal of Medical and Dental Sciences. 2019 Jul; 8(2): 1766-1774en_US
dc.identifier.issn2454-8952
dc.identifier.issn2320-1118
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/183634
dc.languageenen_US
dc.publisherDr. J.S. Sodhi Memorial Educational Societyen_US
dc.relation.issuenumber2en_US
dc.relation.volume8en_US
dc.source.urihttps://doi.org/10.18311/ijmds/2019/23420en_US
dc.subjectCost-Effectivenessen_US
dc.subjectGlaucomaen_US
dc.subjectPharmacoeconomicsen_US
dc.subjectPOAGen_US
dc.subjectPharmacyen_US
dc.titleA Pharmacoeconomic Analysis to Determine the Relative Cost-effectiveness of Timolol 0.5%, Brinzolamide 1% and Brimonidine 0.2% Eye Drops in Treatment of Primary Open Angle Glaucoma/Ocular Hypertensionen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
23420-35154-1-PB.pdf
Size:
534.57 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Medical and Dental Sciences